(VIANEWS) – The NYSE ended the session with Eli Lilly and Company rising 5.17% to $311.80 on Thursday, after five sequential sessions in a row of losses. NYSE fell 0.84% to $14,116.59, after two consecutive sessions in a row of losses, on what was a somewhat bearish trend trading session today.

About Eli Lilly and Company

Eli Lilly and Company develops and markets pharmaceuticals for human use worldwide. Basaglar is available, as well as Humalog Mix 75/25 and Humalog U100. Humalog U200 and Humalog Mix 50/50. It also offers insulin lispro and insulin lispro protamine. Insulin lispro 75/25 and Humulin 70/30 and Humulin N and Humulin R for diabetes. Jardiance and Trulicity are offered for type 2. Alimta is available for the treatment of non-small-cell lung cancer. Olumiant is available for rheumatoid arthritis; Taltz can be used for plaque psoriasis and psoriatic arthritis. Cymbalta is available for depression, diabetes peripheral neuropathic, anxiety disorder and fibromyalgia; Emgality can prevent migraines and treat episodic cluster headaches; Zyprexa is for schizophrenia and bipolar I disorder; as well as bipolar maintenance. Bamlanivimab is available for COVID-19, as well as etesevimab and Bebtelovimab. Cialis can be used for benign prostatic hyperplasia and erectile dysfunction. Forteo treats osteoporosis. It has alliances with Incyte Corporation, Boehringer Ingelheim Pharmaceuticals, Inc., Junshi Biosciences, Regor Therapeutics Group, Lycia Therapeutics, Inc., Kumquat Biosciences Inc., Entos Pharmaceuticals Inc., and Foghorn Therapeutics Inc.


Today’s last reported volume for Eli Lilly and Company is 4112140, 62.6% above its average volume of 2528900.

Eli Lilly and Company’s last close was $296.48, 11.59% below its 52-week high of $335.33.

The company’s growth estimates for the current quarter and the next is 5% and 11.7%, respectively.

Eli Lilly and Company’s Revenue

Year-on-year quarterly revenue growth grew by 14.8%, now sitting on 29.32B for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Eli Lilly and Company’s stock is considered to be overbought (>=80).

Eli Lilly and Company’s Stock Yearly Top and Bottom Value

Eli Lilly and Company’s stock is valued at $311.80 at 18:19 EST, under its 52-week high of $335.33 and way higher than its 52-week low of $220.20.

Eli Lilly and Company’s Moving Average

Eli Lilly and Company’s worth is below its 50-day moving average of $316.71 and higher than its 200-day moving average of $287.26.

More news about Eli Lilly and Company (LLY).


Please enter your comment!
Please enter your name here